IRCT20210130050179N1招募中2 期
Safety and efficacy assessment of Synskin triple action eye contour cream (invisible) for reducing periorbital wrinkle, dark circle and puffiness
Iran Avandfar Company0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 years 至 60 years（—）
- 性别
- All
入选标准
- •Male or female aged 30-60 years
- •The presence of periorbital wrinkle, dark circle and puffiness
- •No change in life style during the study
- •Signed informed consent knowingly
排除标准
- •Critical untreated systemic disease in medical history
- •Any facial rejuvenation treatment, including treatment with topical or oral products or supplements during the last four weeks
- •Any facial rejuvenation treatment including rejuvenation devices or surgical procedures and Botox injections during the last four months
- •Sensitivity and allergy to the components of the formulation
- •Use of any eye cream or eye sunscreen cream during the last four weeks
- •Use of anti-wrinkle or brightening cleansers over the past four weeks
- •Pregnancy or lactation
研究者
相似试验
尚未招募
2 期
Safety and efficacy assessment of Synskin Acnes 2 cream” and Acnes 3 cream” for treatment of acneAcne vulgaris.Acne vulgarisL70.0IRCT20190210042676N14Iran Avandfar Company20
进行中（未招募）
3 期
study to access effectiveness of new drug therapy (aspirin,atorvastatin and nicorandil) in covid-19CTRI/2021/04/032648Dr Ambudhar Sharma
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FRovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-NLovo Nordisk A/S288
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FIovo Nordisk A/S372